Bicocca Open Archive

Logo unimib boa
BIAGI, ETTORE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 13.989
AS - Asia 5.494
EU - Europa 4.817
SA - Sud America 762
Continente sconosciuto - Info sul continente non disponibili 429
AF - Africa 130
OC - Oceania 11
Totale 25.632
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 13.250
SG - Singapore 1.959
CN - Cina 1.280
IT - Italia 791
HK - Hong Kong 741
SE - Svezia 718
RU - Federazione Russa 688
VN - Vietnam 672
CA - Canada 648
DE - Germania 619
BR - Brasile 580
UA - Ucraina 494
IE - Irlanda 464
GB - Regno Unito 295
FR - Francia 207
IN - India 183
FI - Finlandia 143
BD - Bangladesh 115
TR - Turchia 88
KR - Corea 78
AR - Argentina 74
NL - Olanda 73
IQ - Iraq 57
AT - Austria 53
ID - Indonesia 53
MX - Messico 53
ES - Italia 51
BE - Belgio 46
PL - Polonia 46
PK - Pakistan 39
ZA - Sudafrica 39
DK - Danimarca 38
JP - Giappone 38
SA - Arabia Saudita 29
PH - Filippine 28
EC - Ecuador 23
BG - Bulgaria 22
VE - Venezuela 19
CL - Cile 18
CO - Colombia 18
UZ - Uzbekistan 16
TN - Tunisia 14
EG - Egitto 12
MY - Malesia 12
ET - Etiopia 11
IL - Israele 11
IR - Iran 11
NP - Nepal 11
RO - Romania 11
CZ - Repubblica Ceca 10
EU - Europa 10
MA - Marocco 10
JM - Giamaica 9
UY - Uruguay 9
AE - Emirati Arabi Uniti 8
BO - Bolivia 8
JO - Giordania 8
KE - Kenya 8
AU - Australia 7
CH - Svizzera 7
KZ - Kazakistan 7
TH - Thailandia 7
AL - Albania 6
AZ - Azerbaigian 6
DZ - Algeria 6
NG - Nigeria 6
BY - Bielorussia 5
CR - Costa Rica 5
MU - Mauritius 5
OM - Oman 5
PY - Paraguay 5
RS - Serbia 5
TW - Taiwan 5
AO - Angola 4
KG - Kirghizistan 4
LT - Lituania 4
MN - Mongolia 4
PE - Perù 4
SN - Senegal 4
TT - Trinidad e Tobago 4
DO - Repubblica Dominicana 3
GR - Grecia 3
HR - Croazia 3
KW - Kuwait 3
NI - Nicaragua 3
NZ - Nuova Zelanda 3
PA - Panama 3
PR - Porto Rico 3
PT - Portogallo 3
SK - Slovacchia (Repubblica Slovacca) 3
SV - El Salvador 3
SY - Repubblica araba siriana 3
XK - ???statistics.table.value.countryCode.XK??? 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AM - Armenia 2
BH - Bahrain 2
GA - Gabon 2
GT - Guatemala 2
HN - Honduras 2
LB - Libano 2
Totale 25.187
Salva come PNG Salva come JPEG
Città #
Ann Arbor 1.605
Ashburn 1.323
Woodbridge 1.238
Singapore 1.096
Fairfield 876
Houston 822
Hong Kong 728
Chandler 717
Wilmington 693
Jacksonville 522
San Jose 471
Toronto 457
Dublin 455
Seattle 388
Frankfurt am Main 350
Cambridge 337
Dearborn 316
Milan 267
New York 247
Beijing 220
Princeton 197
Santa Clara 196
Ho Chi Minh City 191
Los Angeles 174
Council Bluffs 171
Chicago 160
Hanoi 135
Nanjing 135
Hefei 127
The Dalles 114
Shanghai 92
Dallas 88
Lawrence 85
Lachine 83
Lauterbourg 81
Altamura 68
Seoul 68
Buffalo 64
Boardman 60
Dong Ket 60
Moscow 60
Rome 60
São Paulo 57
Vienna 49
San Diego 48
Helsinki 45
Brussels 44
Orem 42
Nanchang 38
Warsaw 37
Montreal 35
Tianjin 35
London 34
Andover 33
Guangzhou 33
Lissone 33
Da Nang 31
Shenyang 31
Fremont 30
Hebei 27
Atlanta 26
Brooklyn 26
Denver 26
Mountain View 26
Rio de Janeiro 26
Stockholm 26
Hangzhou 25
Munich 25
Baghdad 24
Columbus 24
Huizen 23
Amsterdam 22
Tokyo 22
Changsha 21
Zhengzhou 21
Chennai 20
Plovdiv 20
Jakarta 18
Jinan 18
Ningbo 18
Ottawa 18
Poplar 18
Salt Lake City 18
Boston 17
Manchester 17
Mexico City 17
Philadelphia 17
Phoenix 17
Haiphong 16
Jiaxing 16
San Francisco 16
Figino 15
Detroit 14
Falls Church 14
Johannesburg 14
Kocaeli 14
Nürnberg 14
Tashkent 14
Turin 14
Auburn Hills 13
Totale 17.049
Salva come PNG Salva come JPEG
Nome #
Treatment of Graft versus Host Disease with Mesenchymal Stromal Cells: A Phase I Study on 40 Adult and Pediatric Patients 496
Phase II Study of Sequential Infusion of Donor Lymphocyte Infusion and Cytokine-Induced Killer Cells for Patients Relapsed after Allogeneic Hematopoietic Stem Cell Transplantation 476
Sleeping Beauty-engineered CAR T cells achieve anti-leukemic activity without severe toxicities 466
Acute Myeloid Leukemia Targeting by Chimeric Antigen Receptor T Cells: Bridging the Gap from Preclinical Modeling to Human Studies 446
Targeting CD33 in Chemoresistant AML Patient-Derived Xenografts by CAR-CIK Cells Modified with an Improved SB Transposon System 434
Development of advanced therapies in Italy: Management models and sustainability in six Italian cell factories 429
Preclinical Efficacy and Safety of CD19CAR Cytokine-Induced Killer Cells Transfected with Sleeping Beauty Transposon for the Treatment of Acute Lymphoblastic Leukemia 423
GMP-grade preparation of biomimetic scaffolds with osteo-differentiated autologous mesenchymal stromal cells for the treatment of alveolar bone resorption in periodontal disease 417
Full GMP-Compliant Validation of Bone Marrow-Derived Human CD133+ Cells as Advanced Therapy Medicinal Product for Refractory Ischemic Cardiomyopathy 400
Mesenchymal stromal cells for the treatment of graft-versus-host disease: understanding the in vivo biological effect through patient immune monitoring 396
Balance of Anti-CD123 Chimeric Antigen Receptor Binding Affinity and Density for the Targeting of Acute Myeloid Leukemia 396
Interleukin-17-producing t-helper cells as new potential player mediating graft-versus-host disease in patients undergoing allogeneic stem-cell transplantation 376
TNFRSF13C (BAFFR) positive blasts persist after early treatment and at relapse in childhood B-cell precursor acute lymphoblastic leukaemia 361
Safe and Effective Treatment of Graft Versus Host Disease with Platelet Lysate-Expanded Human Mesenchymal Stromal Cells: A Phase 1 Study On 47 Adult and Pediatric Patients 357
Immunotherapy of acute leukemia by chimeric antigen receptormodified lymphocytes using an improved Sleeping Beauty transposon platform 356
T cells stimulated by CD40L positive leukemic blasts-pulsed dendritic cells meet optimal functional requirements for adoptive T-cell therapy 350
Stable Expression Of Chimeric Antigen Receptors (CARs) By Sleeping Beauty-Mediated Gene Transfer and Efficient Expansion Of Leukemia-Specific Cytokine-Induced Killer (CIK) Cells 347
Regulatory T cells and extracorporeal photochemotherapy: correlation with clinical response and decreased frequency of proinflammatory T cells. 346
Engineered T cells towards TNFRSF13C (BAFFR): a novel strategy to efficiently target B-cell acute lymphoblastic leukaemia 343
Platelet-lysate-expanded mesenchymal stromal cells as a salvage therapy for severe resistant graft-versus-host disease in a pediatric population 341
Characterization of Plated Lysate Cultured Mesenchymal Stromal Cells and Their Potential Use in Tissue-Engineered Osteogenic Devices for the Treatment of Bone Defects 331
Exploration of the lysis mechanisms of leukaemic blasts by chimaeric T-cells 314
Mesenchymal stromal cells do not increase the risk of viral reactivation nor the severity of viral events in recipients of allogeneic stem cell transplantation 314
Characterization of in vitro migratory properties of anti-CD19 chimeric receptor-redirected CIK cells for their potential use in B-ALL immunotherapy 312
Vaccination to improve the persistence of CD19CAR gene-modified T cells in relapsed pediatric acute lymphoblastic leukemia 308
Repeated infusions of donor-derived cytokine-induced killer cells in patients relapsing after allogeneic stem cell transplantation: A phase I study 301
Chimeric Antigen Receptors against CD33/CD123 antigens efficiently target primary Acute Myeloid Leukemia cells in vivo 301
Chimeric T-cell receptors: New challenges for targeted immunotherapy in hematologic malignancies 297
Bath PUVA therapy in pediatric patients with drug-resistant cutaneous graft-versus-host disease 297
Acute myeloid leukemia and novel biological treatments: Monoclonal antibodies and cell-based gene-modified immune effectors 295
Advanced targeted, cell and gene-therapy approaches for pediatric hematological malignancies: results and future perspectives 291
Extracorporeal photochemotherapy is accompanied by increasing levels of circulating CD4+CD25+GITR+Foxp3+CD62L+ functional regulatory T-cells in patients with graft-versus-host disease. 291
Immunosuppression does not affect human bone marrow mesenchymal stromal cell efficacy after transplantation in traumatized mice brain 291
Donor-derived CD19-targeted T cells in allogeneic transplants 290
Cytokine Induced Killer cells for cell therapy of acute myeloid leukemia: improvement of their immune activity by expression of CD33-specific chimeric receptors 288
GMP-based CD133(+) cells isolation maintains progenitor angiogenic properties and enhances standardization in cardiovascular cell therapy 285
Characterization of migratory activity and cytokine profile of helper and cytotoxic CMV-specific T-cell lines expanded by a selective peptide library 280
Targeting of acute myeloid leukaemia by cytokine-induced killer cells redirected with a novel CD123-specific chimeric antigen receptor 277
Upregulation of adhesion molecules on leukemia targets improves the efficacy of cytotoxic T cells transduced with chimeric anti-CD19 receptor 275
Comparison of different suicide-gene strategies for the safety improvement of genetically manipulated T cells 274
Lenalidomide enhances CD23.CAR T cell therapy in chronic lymphocytic leukemia 272
Polyomavirus JC-targeted T-cell therapy for progressive multiple leukoencephalopathy in a hematopoietic cell transplantation recipient 272
A life-threatening paediatric case of acute autoimmune haemolytic anaemia (AIHA) successfully cured by plasma-exchange and combined immunosuppressive treatment 272
Redirecting T cells with Chimeric Antigen Receptor (CAR) for the treatment of childhood acute lymphoblastic leukemia 270
Molecular transfer of CD40 and OX40 ligands to leukemic human B cells induces expansion of autologous tumor-reactive cytotoxic T lymphocytes 269
Targeting of Acute Myeloid Leukemia by Cytokine-Induced Killer Cells Redirected with a Novel CD123-Specific Chimeric Antigen Receptor 268
Development of an alveolar bone regeneration protocol with mesenchyl stem cells for the therapy of severe bone resorption in periodontal disease 263
T lymphocytes redirected against the κ light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells 261
Long-term effects of bone marrow transplantation on dental status in children with leukaemia 261
Allogeneic mesenchymal stem cell infusion for the stabilization of focal segmental glomerulosclerosis 261
TBI, etoposide and cyclophosphamide as a promising conditioning regimen for BMT in childhood ALL in second remission 259
Isolation of monocytes from leukapheretic products for large-scale GMP-grade generation of cytomegalovirus-specific T-cell lines by means of an automated elutriation device 257
Cell-based strategies to manage leukemia relapse: Efficacy and feasibility of immunotherapy approaches 256
Failure of interferon-γ pre-treated mesenchymal stem cell treatment in a patient with crohn's disease 256
Selective elimination of a chemoresistant side population of B-CLL cells by cytotoxic T lymphocytes in subjects receiving an autologous hCD40L/IL-2 tumor vaccine 251
Febrile complications in the first 100 days after bone marrow transplantation in children: a single center's experience 250
The washouts of discarded bone marrow collection bags and filters are a very abundant source of hMSCs 249
Antigen-induced regulatory T cells 246
CD40 activation of BCP-ALL cells generates 11L-10-producing, 11L-12-defective APCs that induce allogeneic T-cell anergy 243
Responses to human CD40 ligand/human interleukin-2 autologous cell vaccine in patients with B-cell chronic lymphocytic leukemia 235
Estudio experimental sobre la utilización de células madre humanas en la terapia de los defectos periodontales: resultados preliminares 234
Immunotherapy of high-risk acute leukemia with a recipient (autologous) vaccine expressing transgenic human CD40L and IL-2 after chemotherapy and allogeneic stem cell transplantation. 232
Induction of antigen-specific regulatory T cells following overexpression of a Notch ligand by human B lymphocytes 232
Bystander transfer of functional human CD40 ligand from gene-modified fibroblasts to B-chronic lymphocytic leukemia cells 231
PTX3 as a potential novel tool for the diagnosis and monitoring of pulmonary fungal infections in immuno-compromised pediatric patients. 230
Chimeric Antigen Receptor for Specific Targeting of Acute Myeloid Leukemia 228
Comparison of two CD40-ligand/interleukin-2 vaccines in patients with chronic lymphocytic leukemia 228
Intrathecal chemotherapy with antineoplastic agents in children 225
Role of early diagnosis for a noninvasive treatment of pulmonary thromboembolism in leukemic children 221
Efficient lentiviral transduction of primary human acute myelogenous and lymphoblastic leukemia cells 212
Overexpression of the Notch ligand, Jagged-1, induces alloantigen-specific human regulatory T cells 211
Human cytotoxic T lymphocytes with reduced sensitivity to Fas-induced apoptosis 211
Selective depletion of a minor subpopulation of B-chronic lymphocytic leukemia cells is followed by a delayed but progressive loss of bulk tumor cells and disease regression. Mol Cancer 206
Mechanical and infective central venous catheter-related complications: a prospective non-randomized study using Hickman and Groshong catheters in children with hematological malignancies 205
Prolonged extracorporeal membrane oxygenation therapy for severe acute respiratory distress syndrome in a child affected by rituximab-resistant autoimmune hemolytic anemia: A case report 204
A persistent severe autoimmune hemolytic anemia despite apparent direct antiglobulin test negativization 203
In Vitro and In Vivo Antitumor Effect of Anti-CD33 Chimeric Receptor-Expressing EBV-CTL against CD33 Acute Myeloid Leukemia 199
CD40 ligand-stimulated B cell precursor leukemic cells elicit interferon-gamma production by autologous bone marrow T cells in childhood acute lymphoblastic leukemia 199
New findings about the Interplay among Clarithromycin, Immune and Central Nervous Systems 195
From Bone Marrow Transplantation to Cellular Therapies: Possible therapeutic strategies in managing autoimmune disorders 189
A Phase 1/2 Study of Autologous Neuroblastoma Tumor Cells Genetically Modified to Secrete IL-2 in Patients With High-risk Neuroblastoma 188
In Vitro Comparison of Three Different Chimeric Receptor-modified Effector T-cell Populations for Leukemia Cell Therapy 187
New advances in leukaemia immunotherapy by the use of Chimeric Artificial Antigen Receptors (CARs): state of the art and perspectives for the near future 184
Effectiveness of extracorporeal photochemotherapy in treating long-term refractory chronic graft-versus-host disease 182
LONG TERM SURVIVAL AND EFFICACY OF HUMAN BONE MARROW MESENCHYMAL STEM CELLS IN TRAUMATIZED MICE BRAIN IS NOT DEPENDENT ON IMMUNOSUPPRESSIVE TREATMENT. 182
Basic biology and clinical application of multipotent mesenchymal stromal cells: from bench to bedside 181
Rapid and efficient nonviral gene delivery of CD154 to primary chronic lymphocytic leukemia cells 169
Mesenchymal stem/stromal cells: a new "cells as drugs" paradigm. Efficacy and critical aspects in cell therapy 169
In vitro and in vivo model of a novel immunotherapy approach for chronic lymphocytic leukemia by anti-CD23 chimeric antigen receptor 164
Long term efficacy of human bone marrow mesenchymal stem cells in traumatized mice brain is not affected by immunosuppressive treatment 164
Phase I Trial of Vaccination With Autologous Neuroblastoma Tumor Cells Genetically Modified to Secrete IL-2 and Lymphotactin 163
LONG TERM EFFICACY OF HUMAN BONE MARROW MESENCHYMAL STEM CELLS IN TRAUMATIZED MICE BRAIN IS NOT AFFECTED BY IMMUNOSUPPRESSIVE TREATMENT. 146
LONG TERM EFFICACY OF HUMAN BONE MARROW MESENCHYMAL STEM CELLS IN TRAUMATIZED MICE BRAIN IS NOT AFFECTED BY IMMUNOSUPPRESSIVE TREATMENT. 129
Low-Dose Lenalidomide Improves CAR-Based Immunotherapy In CLL By Reverting T-Cell Defects In Vivo 90
Totale 25.632
Salva come PNG Salva come JPEG
Categoria #
all - tutte 80.157
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 80.157
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.325 0 135 208 106 71 68 58 66 138 134 98 243
2022/20232.350 271 730 195 222 136 353 24 149 170 6 68 26
2023/20241.345 44 38 61 55 198 347 263 62 110 8 30 129
2024/20252.935 182 328 134 139 252 74 137 116 377 471 236 489
2025/20267.869 780 466 503 844 999 445 960 392 707 686 580 507
2026/2027417 186 231 0 0 0 0 0 0 0 0 0 0
Totale 25.632